Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer

计划入组 10 人 · 首次发布于 2019 年 2 月 4 日

Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

计划入组 58 人 · 首次发布于 2020 年 6 月 23 日

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

计划入组 1 人 · 首次发布于 2024 年 4 月 29 日

177Lu-EB-PSMA-617

Lutetium Lu-177 vipivotide tetraxetan(Pluvicto)

C₄₉H₆₈LuN₉O₁₆

Gallium-68 PSMA-617

ImmusanT, Inc.

United States

LTB4 Sweden AB

Sweden

Hexal AG

Germany

Lutetium-177-PSMA-617 Shows Promise in Advanced Prostate Cancer Treatment

UpFrontPSMA Trial: Lutetium-PSMA Plus Docetaxel Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

Real-World Safety Analysis Reveals Key Adverse Event Patterns for Lutetium-177-PSMA-617 in Advanced Prostate Cancer